REG - BioVentix PLC - Director/PDMR Shareholding

BioventixAnnouncement

29/01/2024 15:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240129:nRSc2629Ba&default-theme=true

RNS Number : 2629B  BioVentix PLC  29 January 2024

Bioventix plc

 

("Bioventix" or "the Company")

 

Director Dealing

 

Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, announces that the Company was notified today that on 29
January 2024 Peter Harrison, Chief Executive Officer of the Company, sold
62,000 ordinary shares of 5 pence each in the Company ("Ordinary Shares"), at
a price of 4,200 pence per Ordinary Share (the "Sale").

 

The Sale was facilitated to enable a new institutional investor to join the
share register. Peter Harrison has undertaken not to dispose of any further
Ordinary Shares for 12 months.

 

Following the Sale, Peter Harrison has a beneficial interest in 297,088
Ordinary Shares, representing approximately 5.7 per cent. of the issued share
capital of the Company.

 

The notification below, made in accordance with the requirements of the EU
Market Abuse Regulation, provides further details.

 

 

For further information please contact:

 

 Bioventix plc                                                Tel: 01252 728 001

 Peter Harrison                     Chief Executive Officer

 Bruce Hiscock                      Chief Financial Officer

 Cavendish Capital Markets Limited                            Tel: 020 7220 0500

 Geoff Nash / Simon Hicks           Corporate Finance

 Nigel Birks / Harriet Ward         Corporate Broking

 

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Peter Harrison
 2.  Reason for the Notification
 a)  Position/status                                              Chief Executive Officer
 b)  Initial notification/Amendment                               Initial notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Bioventix plc
 b)  LEI                                                          213800225MHX7LZQY108
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the Financial instrument, type of instrument  Ordinary Shares of 5 pence each
     Identification code                                          GB00B4QVDF07
 b)  Nature of the transaction                                    Sale of Ordinary Shares
 c)  Price(s) and volume(s)                                       62,000 Ordinary Shares

                                                                  4,200 pence
 d)  Aggregated information:                                      Sale of 62,000 Ordinary Shares at 4,200 pence each

     ·     Aggregated volume

     ·     Price
 e)  Date of the transaction                                      29 January 2024
 f)  Place of the transaction                                     London Stock Exchange, AIM Market (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEASFNAEALEFA